Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03480594 · ClinicalTrials.gov registry record
Effect of Fatty Liver on TCA Cycle Flux and the Pentose Phosphate Pathway
A clinical trial of Fatty Liver, sponsored by University of Texas Southwestern Medical Center.
- Completed
- Registry status
- 22
- Enrollment target
- 1
- Study location
NCT03480594: Completed study of Fatty Liver, sponsored by University of Texas Southwestern Medical Center.
NCT03480594 is a study of Fatty Liver that has completed, run by University of Texas Southwestern Medical Center. The registered enrollment target is 22 participants, below the 210-participant average among 20 other Fatty Liver trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03480594, a study of Fatty Liver, has completed, sponsored by University of Texas Southwestern Medical Center.
- COMPLETED
- Registry status
- 22 participants
- Enrollment target
- 1
- Study location
Study Summary
The investigators plan to evaluate sensitivity and specificity of HP 13C-pyruvate as an imaging agent for detection of altered PDH flux in fatty liver.
Primary Outcome
1\. The ratio of hyperpolarized \[13C\]bicarbonate relative to hyperpolarized \[1-13C\]lactate. This measurement will be monitored from the subject's liver over a \~4 minute period in the MRI system.
Conditions Studied
Interventions
- DRUG MRI Tracer
Study Locations (1)
Texas
- Advanced Imaging Research Center - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2018-10-01 |
| Est. Completion | 2023-10-13 |
What the finished NCT03480594 record still lists
NCT03480594 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 22 participants, a relatively small participant target, below the 210-participant average among 20 other Fatty Liver trials with a reported enrollment target (90% lower).
The record links to 1 condition, with Fatty Liver appearing as the primary indexed condition, and to 1 intervention - of which MRI Tracer is the first listed.
NCT03480594 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT03480594 about?
NCT03480594 is a clinical study titled "Effect of Fatty Liver on TCA Cycle Flux and the Pentose Phosphate Pathway". The investigators plan to evaluate sensitivity and specificity of HP 13C-pyruvate as an imaging agent for detection of altered PDH flux in fatty liver.
What is the current status of trial NCT03480594?
This trial is currently completed. The enrollment target is 22 participants. The study started on 2018-10-01. Estimated completion is 2023-10-13.
What conditions does trial NCT03480594 study?
This clinical trial studies the following conditions: Fatty Liver.
What interventions are being tested in trial NCT03480594?
The interventions under investigation include: MRI Tracer (DRUG).
Who is sponsoring clinical trial NCT03480594?
This trial is sponsored by University of Texas Southwestern Medical Center, which has 837 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03480594 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Fatty Liver
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03480594's enrollment target sits among peer trials
22 17th of 20 higher than 3 of 20 other Fatty Liver trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Fatty Liver trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Intermittent Fasting for NAFLD in Adults
RECRUITING · NA
-
Early Tracking of Childhood Health Determinants (ETCHED) Study
RECRUITING
-
Exploratory Analysis of Enhanced Liver Function (ELF) Test to Detect Early Fatty Liver in High Risk Population
RECRUITING
-
Blood Collection Biorepository for Liver Disease Research
RECRUITING
-
Ph 2 Study of the Safety and Efficacy of Three HU6 Dose Levels and Placebo in Nonalcoholic Steatohepatitis
ACTIVE NOT RECRUITING · Phase 2
-
Liver Positron Emission Tomography (PET) Study of Non Alcoholic Fatty Liver Disease
COMPLETED · Early Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02508038 · 22 participants · Phase 1
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
- NCT03099356 · 22 participants · Phase 2
Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer
- NCT03676647 · 22 participants
Diagnostic DNA Methylation Signature in Diagnosing Thyroid Cancer After Fine-Needle Aspiration in Patients With Thyroid Nodules
- NCT04569591 · 22 participants · NA
DDAVP for Pituitary Adenoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI